MindWalk Holdings (HYFT) Current Leases (2020 - 2026)
MindWalk Holdings (HYFT) posted quarterly Current Leases of $2.2 million for Q2 2026, down 72.42% year-over-year from $8.1 million in Q2 2025, and little changed quarter-over-quarter from $2.2 million in Q1 2026.
MindWalk Holdings (HYFT) Current Leases (2020 - 2026) Analysis & Trends
MindWalk Holdings (HYFT) has reported Current Leases for 7 consecutive years, with $2.2 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Current Leases fell 72.42% year-over-year to $2.2 million; the TTM figure through Apr 2026 stood at $2.2 million (down 72.42% YoY), while the FY2026 annual figure was $2.2 million, down 73.01% from the prior year.
- Current Leases held at $2.2 million in Q2 2026 per HYFT's latest filing, from $2.2 million in the prior quarter.
- Across five years, Current Leases topped out at $9.3 million in Q1 2024 and bottomed at $634462.1 in Q3 2022.
- Historically, Current Leases has averaged $5.0 million across 5 years, with a median of $4.6 million in 2023.
- Annual changes were most pronounced in 2023 — Current Leases soared 935.96% — and 2025, when it sank 72.95%.
- MindWalk Holdings' Current Leases stood at $4.2 million in 2022, then surged by 52.69% to $6.4 million in 2023, then surged by 34.42% to $8.5 million in 2024, then tumbled by 72.95% to $2.3 million in 2025, then fell by 3.13% to $2.2 million in 2026.
- Business Quant data shows HYFT's Current Leases at $2.2 million in Q2 2026, $2.2 million in Q1 2026, and $2.3 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 720.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 11.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 16.75 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 21.95 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 2.24 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 45.93 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.27 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 12.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 2.24 Mn |
| Jan 31, 2026 | 2.23 Mn |
| Oct 31, 2025 | 2.31 Mn |
| Jul 31, 2025 | 2.41 Mn |
| Apr 30, 2025 | 8.12 Mn |
| Jan 31, 2025 | 7.92 Mn |
| Oct 31, 2024 | 8.55 Mn |
| Jul 31, 2024 | 8.69 Mn |
| Apr 30, 2024 | 8.94 Mn |
| Jan 31, 2024 | 9.34 Mn |
| Oct 31, 2023 | 6.36 Mn |
| Jul 31, 2023 | 6.57 Mn |
| Apr 30, 2023 | 4.55 Mn |
| Jan 31, 2023 | 4.58 Mn |
| Oct 31, 2022 | 4.16 Mn |
| Jul 31, 2022 | 634,462.14 |
| Apr 30, 2022 | 779,290.92 |
| Jan 31, 2022 | 775,860.16 |
| Oct 31, 2021 | 762,824.82 |
| Jul 31, 2021 | 806,657.19 |